

WAYFIND-R: A global, real-world precision oncology registry–socioeconomic features




Allan Hackshaw,¹ Rodrigo Dienstmann,² Christophe Le Tourneau,³ Jan Geissler,⁴ Ana Ferro,⁵ Erika Schirghuber,⁶ Olga Skatkova,⁶ Jean-Yves Blay⁷


¹UCL Cancer Institute, London, UK; ²Oncoclínicas Precision Medicine, Oncoclínicas Grupo, São Paulo, Brazil; ³Institut Curie, Paris, France; ⁴Patvocates, Munich, Germany; ⁵Roche Products Limited, Welwyn Garden City, UK; ⁶F. Hoffmann-La Roche Ltd, Basel, Switzerland; ⁷Centre Léon Bérard, Lyon, France

Supplemental Figure 1. WAYFIND-R data collection and analysis

A) Timeline for data collection



B) Patient attrition



*Observation periods are within 6 months of the first observation visit completion date and at least every 6 months thereafter.

[†]Complete baseline means that sites checked that they completed collection of baseline information on entry of the patient into the registry. It also signals if the patient will continue the participation in the registry.

[‡]Sum of totals might be higher than 1,388 as "Continue to next data collection" and "Death" can be selected as reason for end of study.

[§]Patients who ended participation still consented to have the data available in the database. Those that requested data deletion are not included in this analysis cohort.

^{||}For patients currently participating in a clinical trial, data collection is paused while enrolled in the clinical trial, and baseline information is available. These patients will resume follow-up once participation in the clinical trial is over.

Supplemental Table 1. Demographics and clinical characteristics of patients enrolled in WAYFIND-R by cancer type

	Total (n = 1,388)	Breast (n = 102)	Colon (n = 147)	Lung (n = 400)	Ovary (n = 64)	Pancreas (n = 118)	All other cancers (n = 559)
Median age at diagnosis, years (range)	62 (15–91)	47 (25–81)	60 (24–88)	65 (28–90)	60 (28–85)	66 (34–91)	61 (15–91)
Sex							
Female	693 (49.9)	101 (99.0)	64 (43.5)	174 (43.5)	64 (100)	57 (48.3)	233 (41.7)
Male	694 (50.0)	0	83 (56.5)	226 (56.5)	0	60 (50.9)	325 (58.1)
Missing	1 (< 1)	0	0	0	0	0	1 (< 1)
Race							
Asian	155 (11.2)	3 (2.9)	17 (11.6)	68 (17.0)	2 (3.1)	12 (10.2)	53 (9.5)
Black	4 (< 1)	1 (1.0)	0	2 (< 1)	0	0	1 (< 1)
White	711 (51.2)	45 (44.1)	0	185 (46.3)	38 (59.4)	59 (50.0)	312 (55.8)
Mixed/other	101 (7.3)	18 (17.7)	8 (5.4)	28 (7.0)	1 (1.6)	6 (5.1)	40 (7.2)
Not reported*	415 (29.9)	33 (32.4)	50 (34.0)	117 (29.3)	23 (35.9)	40 (33.9)	152 (27.2)
Missing	2 (< 1)	1 (1.0)	0	0	0	0	1 (< 1)
Performance status assessed at baseline							
No	254 (18.3)	17 (16.7)	29 (19.6)	75 (18.8)	17 (26.6)	13 (11.0)	103 (19.4)
Yes - ECOG PS	1,094 (78.8)	79 (77.5)	116 (78.9)	316 (79.0)	46 (71.9)	103 (87.3)	434 (77.6)
0	564 (40.6)	46 (58.2)	60 (51.7)	151 (47.8)	29 (63.0)	43 (41.8)	235 (54.2)
1	395 (28.5)	23 (29.1)	44 (37.9)	127 (40.1)	11 (23.9)	46 (44.7)	144 (33.2)
≥2	123 (8.9)	10 (12.7)	12 (10.3)	32 (10.1)	6 (13.0)	13 (12.6)	50 (11.5)
Missing	12 (< 1)	0	0	6 (1.9)	0	1 (1.0)	5 (1.2)
Yes - Karnofsky	19 (1.4)	5 (4.9)	1 (< 1)	5 (1.3)	0	1 (< 1)	7 (1.3)
Missing	21 (1.5)	1 (1.0)	1 (< 1)	2 (< 1)	1 (1.6)	1 (< 1)	15 (2.7)
Cancer stage at diagnosis [†]							
0	6 (< 1)	0	2 (1.7)	1 (< 1)	0	0	3 (< 1)
I	55 (5.4)	7 (8.6)	1 (< 1)	15 (4.8)	1 (2.2)	1 (1.2)	30 (8.0)
II	62 (6.1)	20 (24.7)	6 (5.0)	8 (2.6)	3 (6.5)	7 (8.3)	18 (4.8)
III	126 (12.4)	15 (18.5)	10 (8.4)	38 (12.2)	19 (41.3)	10 (11.9)	34 (9.0)
IV	598 (58.7)	28 (34.6)	82 (68.9)	209 (70.0)	20 (43.5)	55 (65.5)	204 (54.1)
Not reported	148 (14.5)	8 (9.9)	17 (14.3)	36 (11.5)	2 (4.4)	8 (9.5)	77 (20.4)
Missing	24 (2.4)	3 (3.7)	1 (< 1)	5 (1.6)	1 (2.2)	3 (3.6)	11 (2.9)
Presence of metastases at baseline							
No	231 (16.6)	22 (21.6)	12 (8.2)	72 (18.0)	11 (17.2)	14 (11.9)	101 (18.1)
Yes	1,098 (79.1)	76 (74.5)	132 (89.8)	313 (78.3)	48 (75.0)	102 (86.4)	428 (76.6)
Unknown	38 (2.7)	4 (3.9)	2 (1.4)	13 (3.3)	4 (6.3)	1 (< 1)	14 (2.5)
Missing	21 (1.5)	0	1 (< 1)	2 (< 1)	1 (1.6)	1 (< 1)	16 (2.9)

Data are n (%) and refer to enrolment/baseline unless stated otherwise.

*Not routinely collected at some sites. [†]Staging available at baseline.

ECOG PS, Eastern Cooperative Oncology Group performance status.

Please contact the lead author at a.hackshaw@ucl.ac.uk for permission to reprint and/or distribute. Presented at the ISPOR EU 2023, 12–15 Nov, 2023, Copenhagen, Denmark.

References

1. Le Tourneau C, et al. *JCO Precis Oncol* 2022; 6:e2200019

Acknowledgements

We thank the patients and their families who take part in WAYFIND-R, as well as the staff, research coordinators, and investigators at each participating institution. Research support for third-party writing/printing assistance for this poster, furnished by Eleanor Porteous, MSc, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd.

Disclosures

AH reports conflicts of interest with F. Hoffmann-La Roche Ltd, Illumina, Thermo Fisher, MSD, Takeda, BMS, Boehringer Ingelheim, Celgene, AbbVie, AstraZeneca, Daiichi Sankyo, Merck Serono, Merck/MSD, UCB and Grail, Inc. All authors received research support in the form of third-party medical writing assistance for this poster from F. Hoffmann-La Roche Ltd. Please refer to the abstract for all author conflicts of interest. This analysis was sponsored by F. Hoffmann-La Roche Ltd.